– In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression
Tag: BridgeBio Pharma
BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update
– Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) has now completed last patient last visit and remains on track for topline month 30 registrational data to be announced in late July 2023 – Positive results announced in Cohort 5 of Phase 2 PROPEL 2 trial […]
Recent
Parasol Med Tech Secures $2.75M to Improve Stroke Prevention in Atrial Fibrillation
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
Elucid Statement on Heartflow Lawsuit: Reaffirms Mission, Confidence in Its Technology, and Commitment to Patients and Physicians
Popular
- No commented posts yet